bluebird bio, Inc. (BLUE)
Company Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases.
Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.
The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia.
It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010.
bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
Country | United States |
Founded | 1992 |
IPO Date | Jun 19, 2013 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 323 |
CEO | Andrew Obenshain |
Contact Details
Address: 455 Grand Union Boulevard Somerville, Massachusetts 02145 United States | |
Phone | 339-499-9300 |
Website | bluebirdbio.com |
Stock Details
Ticker Symbol | BLUE |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001293971 |
CUSIP Number | 09609G100 |
ISIN Number | US09609G1004 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Andrew Obenshain | President, Chief Executive Officer and Director |
Thomas J. Klima | Chief Commercial Officer and Chief Operating Officer |
Richard A. Colvin M.D., Ph.D. | Chief Medical Officer |
Christopher Krawtschuk CPA | Chief Financial Officer, Principal Accounting Officer and Treasurer |
Joseph D. Vittiglio Esq., J.D. | Chief Legal and Business Officer and Secretary |
Jess Rowlands | Head of Corporate Communications |
Andrea Walton | Chief People Officer |
Kasra Kasraian | Senior Vice President of Technical Development and Operations |
Scott Shoemaker | Senior Vice President of Quality |
Sarah Alspach | Senior Vice President of External Affairs |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 26, 2024 | 8-K | Current Report |
Mar 26, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
Mar 18, 2024 | 8-K | Current Report |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 6, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Jan 25, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |